Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1285-1289

  Barabutis, Nektarios ^a   Siejka, Agnieszka ^a   Schally, Andrew V ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Growth factor; Growth hormone releasing hormone; Growth hormone releasing hormone receptor

Indexed keywords

BINDING PROTEIN; CYCLIN D3; CYCLINE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE ANALOG; HORMONE ANTAGONIST; JI 38; MZ 5 156; PROTEIN CTBP1; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOTHALAMUS; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ALCOHOL OXIDOREDUCTASES; ANIMALS; CELL LINE, TUMOR; CYCLIN D3; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GROWTH HORMONE-RELEASING HORMONE; HELA CELLS; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950419066     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000613     Document Type: Article

References (33)

1. Thorner MO: The discovery of growth hormone-releasing hormone. J Clin Endocrinol Metab 84: 4671-4676, 1999.
2. Kiaris H, Schally AV and Kalofoutis A: Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 70: 1-24, 2005.
3. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J and Cunha SR: Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 55: 237-266, 2000.
4. Schally AV: New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 40: 315-322, 2008.
5. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A and Kiaris H: Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 104: 5575-5579, 2007.
6. Barabutis N, Siejka A, Schally AV, Block NL, Cai R and Varga JL: Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. J Mol Endocrinol 44: 127-134, 2010.
7. Siejka A, Schally AV and Barabutis N: Activation of Janus kinase/signal transductor and activator of transcription 3 pathway by growth hormone-releasing hormone. Cell Mol Life Sci (In press).
8. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H and Kalofoutis A: Ligand-dependent and - independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 100: 9512-9517, 2003.
9. Barabutis N and Schally AV: Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 98: 1790-1796, 2008.
10. Kiaris H, Schally AV, Varga JL, Groot K and Armatis P: Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96: 14894-14898, 1999.
11. Barabutis N and Schally AV: Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA 105: 20470-20475, 2008.
12. Engel JB and Schally AV: Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3: 157-167, 2007.
13. Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K and Schally AV: Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 92: 4872-4876, 1995.
14. Kiaris H, Koutsilieris M, Kalofoutis A and Schally AV: Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opin Investig Drugs 12: 1385-1394, 2003.
15. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, Nagy A, Kele Z and Schally AV: Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 423-430, 1997.
16. Moldovan GL, Pfander B and Jentsch S: PCNA, the maestro of the replication fork. Cell 129: 665-679, 2007.
17. Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28: 2925-2939, 2009.
18. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
19. Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N and Grossman SR: Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 26: 2360-2372, 2006.
20. Wang SY, Iordanov M and Zhang Q: c-Jun NH2-terminal kinase promotes apoptosis by down-regulating the transcriptional co-repressor CtBP. J Biol Chem 281: 34810-34815, 2006.
21. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW and Goodman RH: Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103: 9029-9033, 2006.
22. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N and Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31: 14-24, 1995.
23. Zeitler P and Siriwardana G: Stimulation of mitogen-activated protein kinase pathway in rat somatotrophs by growth hormone-releasing hormone. Endocrine 12: 257-264, 2000.
24. Bartkova J, Lukas J, Strauss M and Bartek J: Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 17: 1027-1037, 1998.
25. Carnero A: Targeting the cell cycle for cancer therapy. Br J Cancer 87: 129-133, 2002.
26. Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566, 2009.
27. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E and Gudkov AV: Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21: 153-157, 2002.
28. Zhang Z, Li M, Wang H, Agrawal S and Zhang R: Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636-11641, 2003.
29. Morris GF, Bischoff JR and Mathews MB: Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 93: 895-899, 1996.
30. Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723, 2009.
31. Banks D, Wu M, Higa LA, Gavrilova N, Quan J, Ye T, Kobayashi R, Sun H and Zhang H: L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 5: 1719-1729, 2006.
32. Yang J, Kong X and Hanson RW: C-Terminal Binding Protein 1 (CTBP1) and the redox control the PEPCK-C gene transcription. FASEB J 22: 782-785, 2008.
33. Janssen-Heininger YM, Mossman BT, Heintz NH, Forman HJ, Kalyanaraman B, Finkel T, Stamler JS, Rhee SG and van der Vliet A: Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med 45: 1-17, 2008.